In animal experiments, the expression of the MAPK-related gene P38 was increased in the NAFLD group, and the expression of ERK1/2 was decreased, which is consistent with the results of some clinical studies in nonalcoholic fatty liver groups [49, 50]. This evidence concerns the gene MAPK3 and metabolic dysfunction-associated steatotic liver disease.